Methods for treating or preventing symptoms of hormonal variations

Abstract

A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT 2A ) and a dopamine type 2 (D 2 ) receptors.

1 . A method for treating or preventing symptoms of hormonal variation, comprising: administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT 2A ) receptor and a dopamine type 2 (D 2 ) receptor, and wherein the symptoms of hormonal variation are associated with perimenopause or postmenopause. 
   
   
       2 . The method of  claim 1 , wherein the symptoms of hormonal variation comprises at least one selected from hot flashes, dizziness, nausea, headaches, palpitations, profuse sweating, and night sweats. 
   
   
       3 . The method of  claim 1 , wherein the receptor antagonist is at least one selected from risperidone, 9-hydroxyrisperidone, quetiapine, clozapine, otanzapine, aripiprazole, ziprasidone, and zotepine. 
   
   
       4 . The method of  claim 1 , wherein the receptor antagonist is risperidone. 
   
   
       5 . The method of  claim 4 , wherein the effective amount of risperidone is from 0.1 to 50 mg per day for an adult patient. 
   
   
       6 . The method of  claim 4 , wherein the effective amount of risperidone is from 0.1 to 20 mg per day for an adult patient. 
   
   
       7 . The method of  claim 4 , wherein the effective amount of risperidone is from 0.1 to 6 mg per day for an adult patient. 
   
   
       8 . The method of  claim 4 , wherein the effective amount of risperidone is from 0.1 to 2 mg per day for an adult patient. 
   
   
       9 . The method of  claim 1 , wherein the receptor antagonist is 9-hydroxyrisperidone. 
   
   
       10 . The method of  claim 11 , wherein the pharmaceutically acceptable formulation is at least one selected from, oral formulation, injection, inhalation, and transdermal patch. 
   
   
       11 . The method of  claim 1 , wherein the effective amount of the receptor antagonist is administered by using a pharmaceutically acceptable formulation. 
   
   
       12 . The method of  claim 9 , wherein the effective amount of 9-hydroxyrisperidone is from 0.1 to 50 mg per day for an adult patient. 
   
   
       13 . The method of  claim 9 , wherein the effective amount of 9-hydroxyrisperidone is from 0.1 to 20 mg per day for an adult patient. 
   
   
       14 . The method of  claim 9 , wherein the effective amount of 9-hydroxyrisperidone is from 0.1 to 6 mg per day for an adult patient. 
   
   
       15 . The method of  claim 9 , wherein the effective amount of 9-hydroxyrisperidone is from 0.1 to 2 mg per day for an adult patient. 
   
   
       16 . The method of  claim 9 , wherein the effective amount of the receptor antagonist is administered by using a pharmaceutically acceptable formulation. 
   
   
       17 . The method of  claim 16 , wherein the pharmaceutically acceptable formulation is at least one selected from oral formulation, injection, inhalation, and transdermal patch. 
   
   
       18 . The method of  claim 1 , wherein the receptor antagonists is a mixture of risperidone and 9-hydroxyrisperidone.